Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

This study is testing a new drug called TNG260 — either alone or combined with an anti-PD-1 immunotherapy drug — in people with advanced solid tumors that have a mutation in the STK11 gene. This mutation is often linked to poor response to immunotherapy. **You may be eligible if...** - You are 18 years old or older - You have a confirmed advanced or metastatic solid tumor with a documented STK11 mutation - Your cancer is measurable on imaging - Your general health is good (ECOG 0 or 1) - Your organ function (liver, kidneys) meets the required thresholds **You may NOT be eligible if...** - You have a known allergy or sensitivity to TNG260 or to PD-1/PD-L1 antibodies - You have uncontrolled brain metastases - You have active autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding - You have had certain prior treatments that could interact with this study Talk to your doctor to see if this trial is right for you.